Smith & Nephew officials stressed their plan to sell midtier orthopedics in emerging markets during the company's Q3 earnings call, but many are wondering about rumors that CEO Olivier Bohuon is among the contenders in Sanofi's CEO search.
Sales of Teva's multiple sclerosis drug, Copaxone, are still growing--at least for now. The Israeli company's top-seller, whose patent is currently the subject of a Supreme Court appeal, ticked up 5% to reach $1.1 billion in Q3 sales.
Endoscopy system maker EndoChoice is the latest in a series of planned big-ticket med tech IPOs. The startup reportedly plans to file for an IPO on Nasdaq to raise $100 million to $150 million and value the company at as much as $600 million.
Bayer is already coasting along sales-wise, with some powerhouse new drugs helping it beat analysts' third-quarter forecasts. And those sales will only keep on growing, the company said Thursday as it raised its revenue and profit forecasts.
Heska, a Colorado-based maker of veterinary diagnostics and specialty products, announced on Wednesday that its third-quarter earnings jumped 24% from the same period a year ago to $21.8 million, while its net income more than doubled to $513,000. Yet analysts were clearly impatient with the company's efforts to gain more visibility with both customers and investors.
For the now-former chief of Sanofi, Chris Viehbacher, there's plenty of money for a cushion, but it won't be nearly as plump as the packages granted to his counterparts in the U.S.
Abbott has made its move on a trio of med tech startups focused on cardiovascular catheterization. It is buying electrophysiology startup Topera for $250 million plus undisclosed milestones and has secured the right to purchase Advanced Cardiac Therapeutics, which has a novel ablation catheter. Plus, Abbott Ventures participated in a venture round for VytronUS.
Mousera, a healthcare startup focused on bringing current systems research up to speed with modern technology, raised $8.8 million from 9 investors.
Gilead Sciences is charting eye-popping sales for blockbuster Sovaldi and chalking up a key regulatory approval for its new hep C combo pill, Harvoni. But the company's third-quarter earnings fell short of analysts' estimates in light of a hefty Obamacare fee and lower-than-expected revenue for its top-selling hep C drug.
Sanofi's animal health division, Merial, provided a rare bright spot in the company's third-quarter earnings report--but it wasn't quite bright enough to save CEO Chris Viehbacher's job. On Wednesday, just after announcing so-so earnings that triggered a massive selloff of Sanofi's stock, the company's board said it has "decided unanimously to remove" Viehbacher.